First-In-Human Trial Of CRISPR Gene-Editing Therapy Safely Lowered Cholesterol, Triglycerides

First-In-Human Trial Of CRISPR Gene-Editing Therapy Safely Lowered Cholesterol, Triglycerides

Research Highlights: In a Phase 1, first-in-human trial, a one-time infusion of an investigational CRISPR-Cas9 therapy targeting angiopoietin-like protein 3 (ANGPTL3) was safe and reduced LDL choleste...